This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Keryx: Readers React to Perifosine Prediction

Stocks in this article: KERX AEZS

This email from "MR" to Ratain was one of the more entertaining he received:

"Hello Dr. Ratain: I am hoping that AF that's me took your comments regarding perifosine out of context. You should demand an immediate retraction, if he did manipulate your conversation. It is totally out of line for a medical doctor, such as you, involved in medical research to be associating or conversing with such an individual. I am filing a complaint with the SEC about stock manipulation and with your local medical board regarding your lack of ethics and better judgment. You should know better to have any interaction with any financial blogger from TheStreet. It is my goal to have you investigated by the SEC for possible misconduct. Where is your better judgment?"

Sorry to burst the bubble folks, but none of Ratain's comments regarding perifosine were taken out of context or manipulated. I asked him again Tuesday, just to make sure.

Along the same lines, but more polite, "Dean" asks Ratain, "Can you please advise if you have received any consideration, financial or otherwise, in relation to the article that was written about Keryx and Aeterna Zentaris (AEZS) last week?"

Ratain responded to Dean: "I have no financial interest. My relationship with Mr. Feuerstein that's me, again is strictly academic, and emanates from a shared interest in clinical trial design. In that sense, the perifosine phase 2 trial was flawed."

That's a nice segue into a discussion of the published results from a phase II study of perifosine in colon cancer. Many of you wanted to know whether we considered this study -- which purports to demonstrate a survival benefit favoring perifosine over placebo -- into our analysis. Keryx and its supporters believe data from the phase II study bolster the chances for perifosine's success in the ongoing phase III study.

2 of 7

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs